Journal
CLINICAL NEUROPHARMACOLOGY
Volume 29, Issue 1, Pages 15-17Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00002826-200601000-00005
Keywords
Parkinson's disease; methylphenidate; gait; cognitive function; fall risk
Categories
Funding
- NCRR NIH HHS [RR-13622] Funding Source: Medline
- NIA NIH HHS [AG-08812, AG-14100] Funding Source: Medline
- NICHD NIH HHS [HD-39838] Funding Source: Medline
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039838] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR013622] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [P30AG008812, P60AG008812, R29AG014100, R01AG014100] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Twenty-one patients with Parkinson's disease were studied before and 2 h after the administration of a single dose of 20 mg of methylphenidate. In response to methylphenidate, attention significantly improved, whereas memory and visual-spatial performance were unchanged. Gait speed, stride time variability, and Timed Up and Go times (demonstrated measures of fall risk) significantly improved. These findings suggest a new potential pharmacologic means of enhancing mobility and decreasing fall risk in Parkinson's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
